Biotechnology - QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
5/5/2008 3:14:00 PM
[NEWS]Q8003IR Met Primary Endpoints; Demonstrated Strong Reduction of PainIntensity SYDNEY, Australia and BEDMINSTER, N.J., May 5 /PRNewswire-FirstCall/ — QRxPharma Limited (ASX: QRX), aclinical-stage specialty pharmaceutical company focused on the developmentand commercialisation of therapies for pain and central nervous system(CNS) disorders, announced today initial Phase 3 efficacy results forQ8003IR, an immediate release dual-opioid product intended for the acutemanagement of mo…
...
full article